Zynerba Pharmaceuticals, Inc. (ZYNE): Price and Financial Metrics
ZYNE Price/Volume Stats
|Current price||$1.32||52-week high||$1.40|
|Prev. close||$1.34||52-week low||$0.25|
|Day high||$1.33||Avg. volume||471,750|
|50-day MA||$0.94||Dividend yield||N/A|
|200-day MA||$0.57||Market Cap||71.20M|
ZYNE Stock Price Chart Interactive Chart >
Zynerba Pharmaceuticals, Inc. (ZYNE) Company Bio
Zynerba Pharmaceuticals is a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company was founded in 2007 and is based in Devon, Pennsylvania.
ZYNE Latest News Stream
|Loading, please wait...|
ZYNE Latest Social Stream
View Full ZYNE Social Stream
Latest ZYNE News From Around the Web
Below are the latest news stories about ZYNERBA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ZYNE as an investment opportunity.
On September 13, 2023, President Terri Sebree of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) sold 12,401 shares of the company's stock.
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium
Zygel™ (ZYN002) achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment in INSPIRE, a Phase 2 trial with Zygel in children and adolescents with 22q11.2 deletion syndrome (22q)DEVON, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsy
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
With Harmony Biosciences acquiring Zynerba Pharmaceuticals, ZYNE stock jumped on both the buyout and the underlying therapeutic implications.
The centerpiece of Harmony Biosciences' deal is Zynerba's lead new drug candidate Zygel, a pharmaceutically produced transdermal cannabinoid therapy.
ZYNE Price Returns
Continue Researching ZYNEHere are a few links from around the web to help you further your research on Zynerba Pharmaceuticals Inc's stock as an investment opportunity:
Zynerba Pharmaceuticals Inc (ZYNE) Stock Price | Nasdaq
Zynerba Pharmaceuticals Inc (ZYNE) Stock Quote, History and News - Yahoo Finance
Zynerba Pharmaceuticals Inc (ZYNE) Stock Price and Basic Information | MarketWatch